Biota winds back loss, despite legal expenses
Monday, 30 August, 2004
Melbourne-based Biota (ASX:BTA) has reported a loss of $7.8 million, down 25 per cent from its 2003 loss of $10.3 million. This is despite a hefty legal bill of just under $1 million for Biota’s lawsuit against marketing partner GlaxoSmithKline for failure to promote its influenza drug, Relenza.
Biota’s revenues were up 88 per cent to $8.0 million due to increased profit share revenues from diagnostic sales of the company’s FLU OIA and FLU OIA A/B diagnostics product by US marketing partner Thermo Electron -- up 117 per cent to $3.5 million. Royalties from flu therapeutic Relenza were $0.6 million, half of 2003 payments.
Biota announced earlier this month that it would relocate its US research operations -– currently based at Biota Inc in California -- to new facilities in Melbourne in a bid to save costs. Operating expenses decreased by 12 per cent to $16.1 million, as R&D costs were wound back in the US.
Marketing and business development expenses rose to $2.3 million. Biota has cash reserves of $22.9 million, having raised $8.4 million via a share purchase plan in October 2003.
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
Newborns have elevated levels of an Alzheimer's biomarker
What do the brains of newborns and patients with Alzheimer's disease have in common? Both...
Cannabis use may double risk of cardiovascular disease death
Cannabis users have a 29% higher risk of acute coronary syndrome, a 20% higher risk of stroke,...
